QGEN Stock Overview
Offers sample to insight solutions that transform biological materials into molecular insights. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Qiagen N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.99 |
| 52 Week High | US$47.44 |
| 52 Week Low | US$39.03 |
| Beta | 0.37 |
| 1 Month Change | 3.59% |
| 3 Month Change | 0.18% |
| 1 Year Change | 0.48% |
| 3 Year Change | -19.63% |
| 5 Year Change | 30.35% |
| Change since IPO | 2,122.76% |
Recent News & Updates
Recent updates
Qiagen (NYSE:QGEN) Seems To Use Debt Rather Sparingly
Dec 10
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S
Oct 11An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued
Sep 24With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For
May 21Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next
May 03Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly
Mar 20Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)
Feb 13Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings
Jan 23Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold
Sep 09Qiagen: Major Asset Growth Needed In Post-Covid World
Jun 22Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued
Feb 14Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated
Feb 07Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases
Jan 06Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati
Dec 13Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M
Nov 07Qiagen stock down after BHF downgrades rating to Neutral
Oct 10Shareholder Returns
| QGEN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.4% | 0.8% | 0.6% |
| 1Y | 0.5% | -4.9% | 23.7% |
Return vs Industry: QGEN exceeded the US Life Sciences industry which returned -4.9% over the past year.
Return vs Market: QGEN underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| QGEN volatility | |
|---|---|
| QGEN Average Weekly Movement | 2.9% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: QGEN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: QGEN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 5,800 | Thierry Bernard | www.qiagen.com |
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing.
Qiagen N.V. Fundamentals Summary
| QGEN fundamental statistics | |
|---|---|
| Market cap | US$10.00b |
| Earnings (TTM) | US$92.93m |
| Revenue (TTM) | US$1.97b |
107.6x
P/E Ratio5.1x
P/S RatioIs QGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QGEN income statement (TTM) | |
|---|---|
| Revenue | US$1.97b |
| Cost of Revenue | US$663.20m |
| Gross Profit | US$1.30b |
| Other Expenses | US$1.21b |
| Earnings | US$92.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.42 |
| Gross Margin | 66.27% |
| Net Profit Margin | 4.73% |
| Debt/Equity Ratio | 57.0% |
How did QGEN perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 21:32 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Qiagen N.V. is covered by 63 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Catherine Ramsey Schulte | Baird |
| Carla Bänziger | Bank Vontobel AG |